Loss of ATRX or TSC2 has been significantly associated with lymph node metastasis, and combined loss of TSC2 and ATRX has been determined as an independent prognostic factor for shorter RFS in G2 pNENs [105]. Here, ATRX is linked to metastatic malignant neoplasm in the lymph nodes.